AcelRx to Host Second Quarter 2022 Financial Results Call and Webcast on August 11, 2022
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) will release its second quarter financial results on August 11, 2022, after market close. A live webcast and conference call will follow at 4:30 p.m. EDT to discuss the results and business updates. Investors can access the webcast through the company's website, with a replay available for 90 days. AcelRx focuses on innovative therapies, including its approved product, DSUVIA®, and several product candidates aimed at managing severe pain and other medical conditions.
- AcelRx has one approved product in the U.S., DSUVIA®.
- The company is focused on innovative therapies targeting acute pain management.
- None.
HAYWARD, Calif., July 28, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release second quarter financial results after market close on Thursday, August 11, 2022. AcelRx management will host a live webcast and conference call at 4:30 p.m. Eastern Daylight Time/1:30 p.m. Pacific Daylight Time on August 11, 2022 to discuss the financial results and provide an update on the Company's business.
Webcast Information
The webcast can be accessed by visiting the Investors section of the Company's website at www.acelrx.com and clicking on the webcast link on the Investors home page. The webcast will be accompanied by a slide presentation. A webcast replay will be available on the AcelRx website for 90 days following the call and webcast.
Conference Call Information
Investors who wish to participate in the conference call may do so by dialing 1-866-361-2335 for domestic callers, 1-855-669-9657 for Canadian callers, or 1-412-902-4204 for international callers. The conference ID is 10168540.
About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. AcelRx's proprietary, non-invasive sublingual formulation technology delivers sufentanil with consistent pharmacokinetic profiles. The Company has one approved product in the U.S., DSUVIA® (sufentanil sublingual tablet, 30 mcg), known as DZUVEO® in Europe, indicated for the management of acute pain severe enough to require an opioid analgesic for adult patients in certified medically supervised healthcare settings, and several product candidates. The product candidates include: Zalviso® (sufentanil sublingual tablet system, SST system, 15 mcg), an investigational product in the U.S. being developed as an innovatively designed patient-controlled analgesia (PCA) system for reduction of moderate-to-severe acute pain in medically supervised settings; two pre-filled, ready-to-use syringes of ephedrine and phenylephrine licensed for the U.S. from Aguettant; Niyad™, a regional anticoagulant for the extracorporeal circuit; and LTX-608, for the potential treatment of COVID-19, disseminated intravascular coagulation, acute respiratory distress syndrome and acute pancreatitis. DZUVEOis an approved product in Europe.
This release is intended for investors only. For additional information about AcelRx, please visit www.acelrx.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/acelrx-to-host-second-quarter-2022-financial-results-call-and-webcast-on-august-11-2022-301595744.html
SOURCE AcelRx Pharmaceuticals, Inc.
FAQ
When will AcelRx announce its Q2 2022 financial results?
How can I access the AcelRx Q2 earnings call?
What is DSUVIA® and its indication?
What other products is AcelRx developing?
